Low-Intensity Versus Medium-Intensity Continuous Kidney Replacement Therapy for Critically Ill Patients (LIMIT): A Multicenter Randomized Clinical Trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 400
- 试验地点
- 11
- 主要终点
- Composite of death and duration of kidney replacement therapy at 28 days
研究概览
简要总结
This clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy in critically ill patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who meets all of the following criteria and who has given informed consent.
- •Adults (18 years of age or older, regardless of the time since ICU admission) currently admitted to an intensive care unit*.
- •*Includes high care units, where continuous monitoring is conducted and intensive care physicians are in charge of medical care.
- •A diagnosis of acute kidney injury is made according to the Kidney Disease: Improving Global Outcomes (KDIGO) international diagnostic criteria (one of the following is met)
- •Serum creatinine increased by more than 0.3 mg/dL within 48 hours
- •Serum creatinine increased more than 1.5-fold from baseline and the increase is considered to have occurred within 7 days
- •Oliguria (< 0.5 mL/kg/hr) lasting more than 6 hours
- •The treating intensivist believes that continuous kidney replacement therapy is necessary
排除标准
- •Patient who meets any of the following exclusion criteria will be excluded.
- •Receiving chronic dialysis or scheduled for initiation of chronic dialysis
- •Undergoing any kidney replacement therapy or blood purification therapy within 48 hours
- •When kidney replacement therapy using other dialysate or replacement fluids, such as citrate dialysis, is preferred due to coexisting bleeding disorders or allergy to acetate
- •Concomitant blood purification therapy other than hemofiltration/dialysis, such as plasma exchange
- •The patient is in a very critical condition and the treating physician believes that survival for more than 24 hours is unlikely
- •Previous participation in the study
- •After receiving a full explanation of the study and with full understanding, a patient do not consent to participate in the study of their own (or their substitute decision maker's) will.
- •The principal investigator (or an investigator) thinks it to be inappropriate to participate in this study.
研究组 & 干预措施
Medium intensity
25 mL/kg/hr
干预措施: Dialysate fluid, Filtration replacement fluid (Drug)
Low intensity
12 mL/kg/hr
干预措施: Dialysate fluid, Filtration replacement fluid (Drug)
结局指标
主要结局
Composite of death and duration of kidney replacement therapy at 28 days
时间窗: 28 days or hospital discharge whichever comes first
Composite endpoint of death and duration of kidney replacement therapy at 28 days
次要结局
- Serum creatinine level at the end of kidney replacement therapy(90 days or hospital discharge whichever comes first)
- 28-day ventilator-free days(28 days or hospital discharge whichever comes first)
- 28-day vasopressor-free days(28 days or hospital discharge whichever comes first)
- 24-hour urine output at the end of kidney replacement therapy(90 days or hospital discharge whichever comes first)
- ICU mortality(90 days or hospital discharge whichever comes first)
- Hospital mortality(90 days or hospital discharge whichever comes first)
- Dialysis dependence at hospital discharge(90 days or hospital discharge whichever comes first)
研究者
Tomoko Fujii
Professor
Jikei University School of Medicine
